We started the process of determining a valid price forecast for China Pharma Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that China Pharma Holdings Inc ranked in the 10th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for China Pharma Holdings Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is -63.35 -- which is good for besting merely 3.52% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
Its compound free cash flow growth rate, as measured over the past 4.89 years, is -0.07% -- higher than just 20.37% of stocks in our DCF forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CPHI, try CPIX, ENDP, CMD, OSMT, and RVP.